Intrathecal Treatment of Neoplastic Meningitis in Breast Cancer
Author Information
Author(s): Jaeckle K A, Phuphanich S, Bent M J van den, Aiken R, Batchelor T, Campbell T, Fulton D, Gilbert M, Heros D, Rogers L, O'Day S J, Akerley W, Allen J, Baidas S, Gertler S Z, Greenberg H S, LaFollette S, Lesser G, Mason W, Recht L, Wong E, Chamberlain M C, Cohn A, Glantz M J, Gutheil J C, Maria B, Moots P, New P, Russell C, Shapiro W, Swinnen L, Howell S B
Primary Institution: University of California, San Diego
Hypothesis
The study aims to determine the safety and efficacy of DepoCyte for treating neoplastic meningitis due to breast cancer.
Conclusion
DepoCyte showed comparable activity to conventional treatments for neoplastic meningitis due to breast cancer with fewer injections required.
Supporting Evidence
- The response rate among the evaluable patients was 28%.
- The intent-to-treat response rate was 21%.
- Median survival was 88 days.
- 1 year survival is projected to be 19%.
- Major adverse events included headache and arachnoiditis.
Takeaway
This study tested a new medicine for brain problems caused by breast cancer, and it worked well with fewer shots than usual.
Methodology
Patients received DepoCyte injections every 2 weeks for one month, followed by additional treatment for those who responded.
Limitations
The study had a small sample size and a short follow-up period.
Participant Demographics
All patients had metastatic breast cancer with positive CSF cytology or neurologic findings.
Statistical Information
Confidence Interval
95%: 14–41%
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website